NCT02499237View on ClinicalTrials.gov

Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

November 26, 2018

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Denosumab

Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year

DRUG

Zoledronic acid

Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year

Trial Locations (2)

11525

251 Airforce & VA General Hospital, Athens

56429

424 General Military Hospital, Thessaloniki

All Listed Sponsors
collaborator

251 Hellenic Air Force & VA General Hospital

OTHER

collaborator

Leiden University Medical Center

OTHER

lead

424 General Military Hospital

OTHER

NCT02499237 - Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation | Biotech Hunter | Biotech Hunter